Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolizumab + irinotecan liposome + platinum as first-line therapy for extensive-stage small cell lung cancer
ChiCTR2500101196Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab and irinotecan liposome in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
envafolimabirinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500101196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101196.